Health Care & Life Sciences » Pharmaceuticals | Antisense Therapeutics Ltd.

Antisense Therapeutics Ltd. | Income Statement

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
-
3,864.00
1,000.00
69.10
-
Cost of Goods Sold (COGS) incl. D&A
9.80
213.50
317.40
207.80
6.40
Gross Income
9.80
3,650.50
682.60
138.70
6.40
SG&A Expense
4,246.20
3,675.40
3,755.00
3,078.90
2,613.70
EBIT
4,255.90
24.90
3,072.40
3,217.60
2,620.10
Non Operating Income/Expense
18.70
25.80
30.30
7.50
8.90
Pretax Income
4,154.30
1.60
2,910.00
3,154.00
2,603.40
Income Tax
1,141.00
705.30
395.60
399.20
272.40
Consolidated Net Income
3,013.30
706.90
2,514.40
2,754.80
2,331.00
Net Income
3,013.30
706.90
2,514.40
2,754.80
2,331.00
Net Income After Extraordinaries
3,013.30
706.90
2,514.40
2,754.80
2,331.00
Net Income Available to Common
3,013.30
706.90
2,514.40
2,754.80
2,331.00
EPS (Basic)
0.02
0.00
0.01
0.02
0.01
Basic Shares Outstanding
147,034.80
161,080.80
178,774.30
164,821.70
194,630.20
EPS (Diluted)
0.02
0.00
0.01
0.02
0.01
Diluted Shares Outstanding
147,034.80
161,154.20
178,774.30
164,821.70
194,630.20
EBITDA
4,246.20
16.80
3,066.50
3,212.70
2,613.70
Non-Operating Interest Income
82.90
52.30
132.10
71.10
25.60

About Antisense Therapeutics

View Profile
Address
6-8 Wallace Avenue
Toorak Victoria (VIC) 3142
Australia
Employees -
Website http://www.antisense.com.au
Updated 07/08/2019
Antisense Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. It operates through the ATL1102, and ATL1103 segments. The ATL1102 segment represents the second generation antisense inhibitor of CD49d, the alpha subunit of very late antigen-four.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.